Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to identify and eradicate cancerous cells. The company currently oversees six ongoing Phase 2 clinical trials.